Phage therapy program
Locus Biosciences
| Status | Official referral/inquiry route |
|---|---|
| Type | Company |
| Location | Research Triangle Park, North Carolina; United States |
| Entry review | 2026-10-03 |
Access and enquiries
| How to enquire | Company pipeline links to Join the ELIMINATE Trial at eliminateuti.com; current registry confirms recruiting. Trial landing page could not be opened for its application details. |
|---|---|
| Areas of work | LBP-EC01 engineered CRISPR-Cas3 E. coli phage therapy for drug-resistant acute uncomplicated UTI; other pipeline programs are separate development work. |
| International access | No public international-patient eligibility or acceptance policy verified. |
What to confirm
- Trial-only access; no verified general expanded-access policy. Public registry sites use generic Research Site numbers, so it cannot substantiate named treating centers.
Related studies(1)
ELIMINATE
Recruiting
Recorded program–study link. Website
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Program ID | locus |
|---|